secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001140361-26-010651
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Insmed Reports Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE in MAC Lung Disease
--------------------------------------------------------------------------------

- Primary endpoint met: change from baseline in Respiratory Symptom Score at Month 13 showed 17.77 vs 14.66 points (p=0.0299).
- All multiplicity-controlled secondary culture conversion endpoints met: 87.8% vs 57.0% by Month 6, 84.7% vs 61.3% by Month 12 (p<0.0001).
- Durable culture conversion at Month 15: 76.2% vs 47.6% (p<0.0001).
- Plans to file sNDA in U.S. and submit data to PMDA in Japan in H2 2026 for potential label expansion.
- Safety profile consistent with known ARIKAYCE profile; no new safety signals observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126010651/0001140361-26-010651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126010651/ef20068516_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-010651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer